Intragraft nicardipine prophylaxis to prevent no-reflow in triple-vessel saphenous vein graft intervantion

Journal of Invasive Cardiology

Volumn 17, Issue 6, 2005, Pages 334-337

  Fischell, Tim ^a   Haller, Scott ^a   Ashraf, Kamal ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; NICARDIPINE; TROPONIN; VASODILATOR AGENT;

AGED; ANGIOCARDIOGRAPHY; CASE REPORT; CLINICAL FEATURE; CORONARY STENT; ELECTROCARDIOGRAM; HEART MUSCLE NECROSIS; HUMAN; MALE; QUANTITATIVE ANALYSIS; SHORT SURVEY; VEIN GRAFT DISEASE; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; GRAFT OCCLUSION; HEART MUSCLE REPERFUSION; METHODOLOGY; SAPHENOUS VEIN; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSPLANTATION;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MYOCARDIAL REPERFUSION; NICARDIPINE; SAPHENOUS VEIN; STENTS; VASODILATOR AGENTS;

EID: 26044474022     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202.
2. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001;22:729-739.
3. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-782.
4. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-664.
5. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of no reflow after percutaneous coronary intervention. Circulation 1994;89:2514.
6. Fischell TA, Lauer MA. Prevention and management of "no-reflow" during coronary interventions. In: Nissen S, Popma J, Kern M, eds. Cardiac Catheterization and Interventional Self-Assessment Program (CathSap II). Bethesda, Maryland: American College of Cardiology Foundation, 2001.
7. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 1995;75:849-850.
8. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: Comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113-118.
9. Fischell TA, Carter AJ, Foster MT, et al. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:360-365.
10. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000; 12:80-85.
11. Clarke B, Grant D, Patmore L. Comparative calcium entry blocking properties of nicardipine, nifedipine and PY-1 08-68 on cardiac and vascular smooth muscle. Br J Pharmacol 1983;79:333P.
12. Nakaya H, Kanno M. Effects of nicardipine, a new dihydropyridine vasodilator, on coronary circulation and ischemia-induced conduction delay in dogs. Arzneimittel-Forschung 1982;32:626-629.
13. Whiting RL, Dow RJ, Graham DJ, Mroszczak EJ. An overview of the pharmacology and pharmacokinetics of nicardipine. Angiology 1990;41(11R 2):987-991.
14. Lambert CR, Repine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol 1989;64:8H-15H.
15. Singh BN, Josephson MA. Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine. Am Heart J 1990;119 (2 Pt 2):427-434.
16. Haller SD, Mirza R, Kucinich ME, et al. Overestimation of inflated balloon dimensions and risk of stent underexpansion using manufacturer compliance tables: the REALITY trial (abstract). Am J Cardiol TCT-59:26E.
17. Michaels AD, Appleby M, Otten MH, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 2002;14:299-302.
18. Jalinous F, Mooney JA, Mooney MR. Pretreatment with intracoronary diltiazem reduces non-Q-wave myocardial infarction following directional atherectomy. J Invasise Cardiol 1997;9:270-273.